{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"groups":[{"description":"Intravenous (IV) infusions of natalizumab 300 mg once every 28 days for 6 months.","id":"OG000","title":"Natalizumab 300 mg"},{"description":"Intravenous (IV) infusions of natalizumab 450 mg once every 28 days for 6 months.","id":"OG001","title":"Natalizumab 450 mg"}],"populationDescription":"Analysis of binding saturation of α4 integrin sites was not performed because the study was terminated early.","reportingStatus":"POSTED","timeFrame":"Cycle 1: Day 1 (1 hour before infusion and 1 and 24 hours after infusion), Days 8, 15, 22. Cycles 2-5: 1 hour before and 1 hour after infusion). Cycle 6: Day 1 (1 hour before infusion and 1 hour after infusion), Days 8, 15, 22.","title":"Natalizumab Binding Saturation Of α4 Integrin Sites On Peripheral Blood Mononuclear Cells (PBMC)","type":"SECONDARY"}